Back
  1. Home
  2. Profile of Manon Berger (ULiège)
Profil

Berger Manon

Département de pharmacie > Développement de nanomédicaments

CIRM

See author's contact details
ORCID
0000-0001-7237-8246
Main Referenced Co-authors
Piel, Géraldine  (31)
Lechanteur, Anna  (24)
Debuigne, Antoine  (22)
Evrard, Brigitte  (22)
Toussaint, François  (19)
Main Referenced Keywords
biomaterial (7); nanomedicine (7); protein corona (7); Lipoplexes (4); LNP (4);
Main Referenced Unit & Research Centers
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège (13)
CESAM - Complex and Entangled Systems from Atoms to Materials - ULiège (6)
Center for Education and Research on Macromolecules (CERM) (4)
CERM - Center for Education and Research on Macromolecules - ULiège (3)
GIGA Molecular Biology of Diseases-Gene Expression & Cancer - ULiège (3)
Main Referenced Disciplines
Pharmacy, pharmacology & toxicology (25)
Chemistry (10)
Materials science & engineering (7)
Biotechnology (1)

Publications (total 32)

The most downloaded
87 downloads
Degey, M., Berger, M., Evrard, B., & Piel, G. (10 April 2024). Exploring alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. 17th European Symposium on Controlled Drug Delivery. https://hdl.handle.net/2268/316320

The most cited

30 citations (OpenAlex)

Berger, M., Lechanteur, A., Evrard, B., & Piel, G. (2021). Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120851 https://hdl.handle.net/2268/261980

Debuigne, A., Berger, M., Toussaint, F., Ben Djemaa, S., Jérôme, C., Lechanteur, A., Mottet, D., & Piel, G. (07 May 2025). Lipid-poly(N-vinylamide) conjugates as PEG alternatives towards safer and efficient siRNA delivery systems [Paper presentation]. Advanced Polymers via Macromolecular Engineering [APME], Catania, Italy.

Berger, M., Degey, M., Curnel, A., Evrard, B., & Piel, G. (2025). The benefits of emerging alternatives to PEG for lipid nanoparticle RNA delivery systems. Nanomedicine, 1 - 3. doi:10.1080/17435889.2025.2500917
Peer Reviewed verified by ORBi

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Maquoi, E., Leblond Chain Jeanne, & Piel, G. (29 January 2025). ADVANCING siRNA DELIVERY: DSPE-PNMVA AS A SOLUTION TO THE PEG DILEMMA IN LNP [Paper presentation]. CIRM DAY, Liège, Belgium.

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Leblond Chain Jeanne, & Piel, G. (03 December 2024). ADVANCING siRNA DELIVERY: DSPE-PNMVA24 AS A SOLUTION TO THE PEG DILEMMA IN LNP FOR TUMOR TARGETING [Poster presentation]. SF Nano.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Leblond Chain, J., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (December 2024). Development of lipid nanoparticles based on PEG alternatives for efficient siRNA delivery [Paper presentation]. 1Oth annual meeting of SFNano, Toulouse, France.
Peer reviewed

Debuigne, A., Piel, G., Mottet, D., Toussaint, F., Berger, M., Ben Djemaa, S., & Lechanteur, A. (07 November 2024). Polymer derivatives and their use as lipid nanoparticle modifiers.

Debuigne, A., Piel, G., Mottet, D., Toussaint, F., Berger, M., Ben Djemaa, S., & Lechanteur, A. (06 November 2024). Polymer derivatives and their use as lipid nanoparticle modifiers.

Degey, M., Berger, M., Debuigne, A., Jérôme, C., Evrard, B., Leblond Chain, J., & Piel, G. (28 October 2024). Impact of lipid-polymer type and content on Lipid Nanoparticles (LNPs) physico-chemical properties and protein corona formation [Poster presentation]. CRS BNLF Local Chapter, Gand, Belgium.

Debuigne, A., Berger, M., Toussaint, F., Ben Djemaa, S., Jérôme, C., Lechanteur, A., Mottet, D., & Piel, G. (24 April 2024). Poly(N-vinyl amide)-lipid conjugates as poly(ethylene glycol) alternatives for the modification of lipid-based nanocarriers [Paper presentation]. Materials Research Society (MRS) Spring Meeting, Seattle, United States.

Degey, M., Berger, M., Evrard, B., & Piel, G. (10 April 2024). Exploring alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. 17th European Symposium on Controlled Drug Delivery.

Berger, M., Toussaint, F., Ben Djemaa, S., Maquoi, E., Pendeville-Samain, H., Evrard, B., Jérôme, C., Leblond Chain, J., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (March 2024). Innovative siRNA-based lipid nanoparticles decorated with PEG alternatives (PNVP and PNMVA) to circumvent dilemma and immunogenicity [Paper presentation]. 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology, Vienne, Austria.
Peer reviewed

Degey, M., Berger, M., Evrard, B., & Piel, G. (31 January 2024). New amphiphilic polymers with variable length and number of lipid chains as alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. CIRM DAY - Scientific day, Liege, Belgium.

Penoy, N., Delma, K. L., Berger, M., Evrard, B., & Piel, G. (2024). Supercritical fluid methods for liposome production and sterilization. In Antimisiaris Sophia G., Liposomes in drug delivery : what, where, how and when to deliver. Elsevier. doi:10.1016/B978-0-443-15491-1.00003-1
Peer reviewed

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Maquoi, E., Pendeville-Samain, H., Evrard, B., Jérôme, C., Chain, J. L., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (2024). Poly(N-methyl‐N‐vinylacetamide): a strong alternative to PEG for lipid‐based nanocarriers delivering siRNA. Advanced Healthcare Materials, 2302712. doi:10.1002/adhm.202302712
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Berger, M. (2023). Development of lipid nanoparticles based on PEG alternatives for efficient siRNA delivery [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/307614

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Laloy, J., Pendeville-Samain, H., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (02 August 2023). Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. Journal of Controlled Release, 361, 87 - 101. doi:10.1016/j.jconrel.2023.07.031
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (27 April 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticle tracking method [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (21 March 2023). Impact of the hydrophobic chain length of PEG derivatives on the behavior of LNPs in serum: Development of a Nanoparticle Tracking Analysis (NTA) Method [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.
Peer reviewed

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597
Peer Reviewed verified by ORBi

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (01 February 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticles tracking method [Paper presentation]. CIRM Day, Liege, Belgium.

Debuigne, A., Piel, G., Mottet, D., Toussaint, F., Berger, M., Ben Djemaa, S., & Lechanteur, A. (2023). Polymer Derivative and their use as lipid nanoparticle modifiers”.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (15 November 2022). Amphiphilic poly(N-vinylpyrrolidone)-based lipoplex modifiers for drug delivery applications [Paper presentation]. Belgian Polymer Group (BPG) Annual Meeting, Blankenberge, Belgium.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (14 June 2022). Novel polyvinylpyrrolidone-based lipoplex modifiers for siRNA delivery [Poster presentation]. Bordeaux Polymer Conference, Bordeaux, France.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (01 June 2022). PNVP as PEG alternative for lipoplex modification in siRNA delivery application [Poster presentation]. Advanced Functional Polymers for Medecine (AFPM), Nice, France.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (30 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting), Rotterdam, Netherlands.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (09 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 2022 Meeting of the Germany and BeNeLux & France Local Chapters of the Controlled Release Society in Aachen, Aachen, Germany.

Berger, M., Toussaint, F., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (02 February 2022). PNVP-polymers as a promising polyethyleneglycol (PEG) alternative onto anti-tumor lipoplexes surface [Paper presentation]. CIRM-Day, Liege, Belgium.

Berger, M., Lechanteur, A., Evrard, B., & Piel, G. (2021). Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120851
Peer Reviewed verified by ORBi

Toussaint, F., Berger, M., Sanaa, B. D., Lechanteur, A., Jérôme, C., Piel, G., Mottet, D., & Debuigne, A. (27 May 2021). Polyvinylpyrrolidone compounds as PEG alternatives for lipoplex modification [Poster presentation]. Belgian Polymer Group (BPG) Annual Meeting, remote, Belgium.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Debuigne, A., Mottet, D., Lechanteur, A., & Piel, G. (May 2021). Impact of amphiphilic N-vinyl pyrrolidone-based polymers used as PEG alternative on lipoplexes physico-chemical properties, cytotoxicity and gene delivery [Poster presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (06 April 2021). Amphiphilic N-vinyl pyrrolidone-based polymers as PEG alternatives to avoid blood proteins adsorption around liposomes [Paper presentation]. Early Career Scientist Meeting 2021.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (04 March 2021). Impact of amphiphilic copolymer used as PEG alternative on the formation of a protein corona around coated-liposomes encapsulating siRNA [Paper presentation]. 2021 - Virtual Local Chapter Meeting Germany and BeNeLux & France, Aachen, Germany.

Contact ORBi